117 related articles for article (PubMed ID: 7519652)
1. Marker determination for response monitoring: radiotherapy and disappearance curves.
Becciolini A; Porciani S; Lanini A
Int J Biol Markers; 1994; 9(1):38-42. PubMed ID: 7519652
[TBL] [Abstract][Full Text] [Related]
2. Serum amylase and tissue polypeptide antigen as biochemical indicators of salivary gland injury during iodine-131 therapy.
Becciolini A; Porciani S; Lanini A; Benucci A; Castagnoli A; Pupi A
Eur J Nucl Med; 1994 Oct; 21(10):1121-5. PubMed ID: 7828622
[TBL] [Abstract][Full Text] [Related]
3. Serial measurements of tissue polypeptide specific antigen (TPS), PSA, PAP and CEA serotest values in treated patients with primary and metastatic prostate cancer.
Tarle M
Anticancer Res; 1993; 13(3):769-77. PubMed ID: 7686362
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of tissue polypeptide antigen (TPA) in head and neck carcinomas.
Becciolini A; Porciani S; Lanini A; Tommasi M; Olmi P; Chiavacci A
Acta Oncol; 1993; 32(3):295-9. PubMed ID: 8323767
[TBL] [Abstract][Full Text] [Related]
5. Serum tissue polypeptide antigen (TPA) and prostatic acid phosphatase (PAP) in patients with prostatic cancer.
Marczyńska A; Kulpa J; Leńko J; Augustyn M
Int Urol Nephrol; 1988; 20(2):123-9. PubMed ID: 2454895
[TBL] [Abstract][Full Text] [Related]
6. Comparative experimental study of the serum prostate specific antigen and prostatic acid phosphatase in serially transplantable human prostatic carcinoma lines in nude mice.
Csapo Z; Brand K; Walther R; Fokas K
J Urol; 1988 Nov; 140(5):1032-8. PubMed ID: 2459419
[TBL] [Abstract][Full Text] [Related]
7. Tissue polypeptide antigen (TPA) as a prognostic aid in human prostatic carcinoma.
Lewenhaupt A; Ekman P; Eneroth P; Nilsson B; Nordström L
Prostate; 1985; 6(3):285-91. PubMed ID: 3991370
[TBL] [Abstract][Full Text] [Related]
8. Serum TPS, PSA, and PAP values in relapsing stage D2 adenocarcinoma of the prostate.
Kraljić I; Kovacić K; Tarle M
Urol Res; 1994; 22(5):329-32. PubMed ID: 7533445
[TBL] [Abstract][Full Text] [Related]
9. Clinical usefulness of prostate-specific antigen and prostatic acid phosphatase in patients with prostatic cancer.
Filella X; Molina R; Jo J; Umbert B; Bedini JL; Ballesta AM
Tumour Biol; 1990; 11(6):289-94. PubMed ID: 1700860
[TBL] [Abstract][Full Text] [Related]
10. Tissue polypeptide-specific antigen: a discriminative parameter between prostate cancer and benign prostatic hypertrophy.
Marrink J; Oosterom R; Bonfrer HM; Schröder FH; Mensink HJ
Eur J Cancer; 1993; 29A(4):570-1. PubMed ID: 7679580
[TBL] [Abstract][Full Text] [Related]
11. [Role of the markers PAP-PSA in the diagnosis of cancer of the prostate].
Petrone U; Gaspari G; Marascia G; Magnocavallo N; Petrone D; Tucci C
Minerva Urol Nefrol; 1990; 42(2):73-5. PubMed ID: 1697431
[TBL] [Abstract][Full Text] [Related]
12. Correlation of cell proliferation marker (TPS), natural killer (NK) activity and tumor load serotest (PSA) in untreated and treated prostatic tumors.
Tarle M; Kovacić K; Kastelan M
Anticancer Res; 1993; 13(1):215-8. PubMed ID: 7682800
[TBL] [Abstract][Full Text] [Related]
13. Serum tissue polypeptide antigen (TPA): a marker of acute injury of salivary glands during radiation therapy.
Becciolini A; Tommasi MS; Porciani S; Fantappiè B; Cellai E; Chiavacci A
Int J Radiat Oncol Biol Phys; 1987 Sep; 13(9):1339-42. PubMed ID: 3624042
[TBL] [Abstract][Full Text] [Related]
14. Proposal for biochemical dosimeter for prolonged space flights.
Becciolini A; Porciani S; Lanini A; Balzi M; Faraoni P
Phys Med; 2001; 17 Suppl 1():185-6. PubMed ID: 11776255
[TBL] [Abstract][Full Text] [Related]
15. [Determination of prostatic specific antigen and prostatic acid phosphatase as tumor markers of cancer of the prostate].
Morote Robles J; de Torres Mateos JA
Arch Esp Urol; 1989; 42 Suppl 2():124-30. PubMed ID: 2484148
[TBL] [Abstract][Full Text] [Related]
16. The Diagnostic and Prognostic Value of Tumor Markers (CEA, SCC, CYFRA 21-1, TPS) in Head and Neck Cancer Patients.
Barak V; Meirovitz A; Leibovici V; Rachmut J; Peretz T; Eliashar R; Gross M
Anticancer Res; 2015 Oct; 35(10):5519-24. PubMed ID: 26408719
[TBL] [Abstract][Full Text] [Related]
17. Prostate specific antigen levels after definitive irradiation for carcinoma of the prostate.
Schellhammer PF; Schlossberg SM; el-Mahdi AM; Wright GL; Brassil DN
J Urol; 1991 May; 145(5):1008-10; discussion 1010-1. PubMed ID: 1707987
[TBL] [Abstract][Full Text] [Related]
18. Serum PSA evaluations during salvage radiotherapy for post-prostatectomy biochemical failures as prognosticators for treatment outcomes.
Do T; Dave G; Parker R; Kagan AR
Int J Radiat Oncol Biol Phys; 2001 Aug; 50(5):1220-5. PubMed ID: 11483332
[TBL] [Abstract][Full Text] [Related]
19. Use of tumor markers in the management of head and neck cancer.
Rosati G; Riccardi F; Tucci A
Int J Biol Markers; 2000; 15(2):179-83. PubMed ID: 10883893
[TBL] [Abstract][Full Text] [Related]
20. Prostate-specific antigen and prostatic acid phosphatase in the detection of early prostate cancer and in the prediction of regional lymph node metastases.
Wirth MP; Frohmüller HG
Eur Urol; 1992; 21(4):263-8. PubMed ID: 1281102
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
